


Rapidly advancing pipeline of investigational precision therapies



EGFR-m, EGFR mutant; FOP, fibrodysplasia ossificans progressiva; HCC, hepatocellular carcinoma. ¹Unresectable or metastatic disease. ²Phase 1 trial in healthy volunteers.

*CStone Pharmaceuticals has exclusive rights to develop and commercialize avapritinib, BLU-554 and BLU-667 in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains all rights in the rest of the world.

**Blueprint Medicines has U.S. commercial rights for up to two programs. Roche has worldwide commercialization rights for up to three programs and ex-U.S. commercialization rights for up to two programs.